Jefferies Financial Group Reiterates Buy Rating for PureTech Health (LON:PRTC)

PureTech Health (LON:PRTC)‘s stock had its “buy” rating restated by analysts at Jefferies Financial Group in a research note issued to investors on Monday, Marketbeat reports. They presently have a GBX 455 ($5.78) price target on the stock. Jefferies Financial Group’s price objective points to a potential upside of 184.38% from the company’s current price.

PureTech Health Trading Down 5.9 %

PRTC stock opened at GBX 160 ($2.03) on Monday. The business has a fifty day simple moving average of GBX 161.22 and a 200-day simple moving average of GBX 171. PureTech Health has a 52 week low of GBX 138.75 ($1.76) and a 52 week high of GBX 238.50 ($3.03). The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 47.27. The company has a market cap of £383.07 million, a price-to-earnings ratio of -695.65 and a beta of 1.02.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.